ABL1 BCR-ABL F317L

BCR-ABL F317L和类似的BCR-ABL T315I突变一样，正成为CML患者对一线治疗耐药的常见临床标志。已证明它对达沙替尼具有耐药性，但对波纳替尼和其他第二代抑制剂反应良好。
BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors.